000140850 001__ 140850
000140850 005__ 20240229112522.0
000140850 0247_ $$2doi$$a10.1093/neuonc/noy161
000140850 0247_ $$2pmid$$apmid:30277538
000140850 0247_ $$2ISSN$$a1522-8517
000140850 0247_ $$2ISSN$$a1523-5866
000140850 0247_ $$2altmetric$$aaltmetric:49098526
000140850 037__ $$aDKFZ-2018-01605
000140850 041__ $$aeng
000140850 082__ $$a610
000140850 1001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b0$$eFirst author$$udkfz
000140850 245__ $$aN2M2 (NOA20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
000140850 260__ $$aOxford$$bOxford Univ. Press$$c2019
000140850 3367_ $$2DRIVER$$aarticle
000140850 3367_ $$2DataCite$$aOutput Types/Journal article
000140850 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655298739_9350
000140850 3367_ $$2BibTeX$$aARTICLE
000140850 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140850 3367_ $$00$$2EndNote$$aJournal Article
000140850 520__ $$aPatients with glioblastoma without O6-methyl guanine O6-methylatransferase (MGMT) promoter hypermethylation are unlikely to benefit from alkylating chemotherapy with temozolomide (TMZ). Trials aiming at replacing TMZ with targeted agents in unselected patient populations have failed to demonstrate any improvement of survival. Advances in molecular understanding and diagnostic precision enable identification of key genetic alterations in a timely manner and in principle allow treatments with targeted compounds based on molecular markers.The NCT Neuro Master Match (N2M2) trial is an open label multicenter phase I/IIa umbrella trial for patients with newly diagnosed isocitrate dehydrogenase (IDH) wildtype glioblastoma without MGMT promoter hypermethylation to show safety, feasibility and preliminary efficacy of treatment with targeted compounds in addition to standard radiotherapy based on molecular characterization. N2M2 is formally divided in a DISCOVERY and a TREATMENT part. DISCOVERY includes broad molecular neuropathological diagnostics to detect predefined biomarkers for targeted treatments. Molecular diagnostics and bioinformatic evaluation are performed within four weeks, allowing a timely initiation of postoperative treatment. Stratification for TREATMENT takes place in five subtrials, including alectinib, idasanutlin, palbociclib, vismodegib and temsirolimus as targeted therapies, according to the best matching molecular alteration. Patients without matching alterations are randomized between subtrials without strong biomarkers using atezolizumab and asinercept (APG101), and the standard of care, TMZ. For the phase I parts, a Bayesian criterion is used for continuous monitoring of toxicity. In the phase II trials, progression-free survival at six months is used as endpoint for efficacy.
000140850 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000140850 588__ $$aDataset connected to CrossRef, PubMed,
000140850 7001_ $$0P:(DE-He78)8b508b91c472089d47f0930c895fd342$$aDettmer, Susan$$b1$$udkfz
000140850 7001_ $$0P:(DE-HGF)0$$aBerberich, Anne$$b2
000140850 7001_ $$0P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aKessler, Tobias$$b3$$udkfz
000140850 7001_ $$0P:(DE-He78)8d29882b41da204dfb948d6f1238d49f$$aKarapanagiotou-Schenkel, Irini$$b4$$udkfz
000140850 7001_ $$aWick, Antje$$b5
000140850 7001_ $$0P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aWinkler, Frank$$b6$$udkfz
000140850 7001_ $$0P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb$$aPfaff, Elke$$b7$$udkfz
000140850 7001_ $$0P:(DE-He78)fc949170377b58098e46141d95c72661$$aBrors, Benedikt$$b8$$udkfz
000140850 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b9$$udkfz
000140850 7001_ $$aUnterberg, Andreas$$b10
000140850 7001_ $$aBendszus, Martin$$b11
000140850 7001_ $$aHerold-Mende, Christel$$b12
000140850 7001_ $$0P:(DE-He78)cef2261a4b41e6c8b36045623e0a025d$$aEisenmenger, Andreas$$b13$$udkfz
000140850 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b14$$udkfz
000140850 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b15$$udkfz
000140850 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b16$$udkfz
000140850 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b17$$udkfz
000140850 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b18$$eLast author$$udkfz
000140850 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noy161$$n1$$p95-105$$tNeuro-Oncology$$v21$$x1523-5866$$y2019
000140850 909CO $$ooai:inrepo02.dkfz.de:140850$$pVDB
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8b508b91c472089d47f0930c895fd342$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d29882b41da204dfb948d6f1238d49f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fc949170377b58098e46141d95c72661$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cef2261a4b41e6c8b36045623e0a025d$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000140850 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000140850 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000140850 9141_ $$y2019
000140850 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000140850 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2017
000140850 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000140850 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000140850 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000140850 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000140850 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000140850 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000140850 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000140850 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000140850 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2017
000140850 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000140850 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x1
000140850 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x2
000140850 9201_ $$0I:(DE-He78)B330-20160331$$kB330$$lAngewandte Bioinformatik$$x3
000140850 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x4
000140850 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lNeuroimmunologie und Hirntumorimmunologie$$x5
000140850 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPediatric Glioma$$x6
000140850 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x7
000140850 980__ $$ajournal
000140850 980__ $$aVDB
000140850 980__ $$aI:(DE-He78)B320-20160331
000140850 980__ $$aI:(DE-He78)E050-20160331
000140850 980__ $$aI:(DE-He78)B062-20160331
000140850 980__ $$aI:(DE-He78)B330-20160331
000140850 980__ $$aI:(DE-He78)B300-20160331
000140850 980__ $$aI:(DE-He78)D170-20160331
000140850 980__ $$aI:(DE-He78)B360-20160331
000140850 980__ $$aI:(DE-He78)L101-20160331
000140850 980__ $$aUNRESTRICTED